Operating losses remain structural, with the 2026Q1 operating loss of $78.8M highlighting the firm's inability to cover fixed overhead through its $18.3M in milestone-driven revenue.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 |
|---|
| Sales/Revenue | 71.64M | 67.48M | 53.88M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | 5.37% | 25.24% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 3.83M | 57K | 0 | 849K | 0 | 0 | 194K | 0 | 10K | 30K | 31K | 20K | 23.91K | 22.73K | 22.34K | 23.44K | 20.51K | 19.16K | 0 |
| COGS % of Revenue | - | 0.08% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 67.81M | 67.42M | 53.88M | -849K | 0 | 0 | -194K | 0 | -10K | -30K | -31K | -20K | -23.91K | -22.73K | -22.34K | -23.44K | -20.51K | -19.16K | 0 |
| Gross Margin % | 94.66% | 99.92% | 100% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 25.13% | 6446.64% | - | - | 100% | - | 100% | 66.67% | 3.23% | -55% | 16.34% | -5.16% | -1.76% | 4.69% | -14.29% | -7.05% | - | - |
| Operating Expenses | 385.56M | 371.06M | 247.08M | 164.96M | 139.87M | 131.26M | 91.7M | 67.48M | 62.88M | 36.08M | 28.37M | 23.86M | 10.9M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | -33.62K |
| OpEx % of Revenue | - | 549.86% | 458.55% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 128.35M | 119.98M | 77.11M | 50.57M | 47.05M | 46.54M | 31.31M | 19.65M | 16.1M | 9.65M | 7.96M | 6.09M | 3.85M | 22.34K | 23.44K | 20.51K | 20.51K | 19.16K | 0 |
| SG&A % of Revenue | - | 177.8% | 143.11% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 260.36M | 251.07M | 169.97M | 115.23M | 92.81M | 84.72M | 60.4M | 47.83M | 46.79M | 26.43M | 20.4M | 17.78M | 8.05M | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 372.06% | 315.44% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -943K | 0 | 0 | -849K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2M | 0 | 0 | 0 | 0 | 0 | -33.62K |
| Operating Income | -317.75M | -303.63M | -193.19M | -165.8M | -139.87M | -131.26M | -91.9M | -67.48M | -62.88M | -36.08M | -28.37M | -23.86M | -11.8M | -22.34K | -23.44K | -20.51K | -41.02K | -38.32K | -33.62K |
| Operating Margin % | -443.54% | -449.94% | -358.55% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -57.16% | -16.52% | -18.55% | -6.56% | -42.83% | -36.19% | -7.31% | -74.3% | -27.18% | -18.86% | -102.21% | -52726.64% | 4.69% | -14.29% | 50% | -7.05% | -13.96% | - |
| EBITDA | -316.6M | -302.6M | -192.35M | -164.96M | -139.11M | -130.7M | -91.7M | -67.47M | -62.87M | -36.05M | -28.34M | -23.84M | -11.8M | -22.34K | -23.44K | -20.51K | -41.02K | -38.32K | -33.62K |
| EBITDA Margin % | -441.94% | -448.41% | -356.97% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -50.8% | -57.32% | -16.61% | -18.58% | -6.43% | -42.52% | -35.92% | -7.31% | -74.42% | -27.21% | -18.83% | -102.09% | -52713.21% | 4.69% | -14.29% | 50% | -7.05% | -13.96% | - |
| D&A (Non-Cash Add-back) | 1.15M | 1.03M | 848K | 849K | 759K | 558K | 194K | 10K | 10K | 30K | 31K | 20K | 3K | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | -299.24M | -276.86M | -170.35M | -151.08M | -135.61M | -130.05M | -89.05M | -67.48M | -62.88M | -36.08M | -28.37M | -23.86M | -11.8M | -23.64K | -23.71K | -25.15K | -20.51K | -19.16K | 0 |
| Net Interest Income | 23.25M | 25.26M | 21.23M | 13.17M | 4.03M | 792K | 2.22M | 4.09M | 2.2M | -137K | -78K | 40K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 24.33M | 26.77M | 22.85M | 14.72M | 4.25M | 1.21M | 2.8M | 4.67M | 3.17M | 751K | 499K | 128K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.07M | 1.51M | 1.62M | 1.55M | 229K | 414K | 578K | 580K | 970K | 888K | 577K | 88K | 5.88K | 4.97K | 3.6K | 1.89K | 1.89K | 838 | 0 |
| Other Income/Expense | 23.25M | 25.26M | 21.23M | 13.17M | 4.03M | 792K | 2.27M | 4.44M | 2.64M | 943K | 807K | 972K | 879K | 16.86K | 17.37K | 19.84K | 18.62K | 18.32K | 0 |
| Pretax Income | -294.49M | -278.37M | -171.97M | -152.63M | -135.84M | -130.47M | -89.63M | -63.14M | -60.45M | -35.43M | -27.56M | -22.63M | -11.01M | -27.32K | -27.04K | -22.39K | -22.39K | -20K | -33.62K |
| Pretax Margin % | -411.08% | -412.51% | -319.15% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 79K | 297K | 2.02M | 0 | 0 | 0 | 0 | 0 | 0 | -30K | -31K | -20K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.03% | -0.11% | -1.17% | 0% | 0% | 0% | 0% | 0% | 0% | 0.08% | 0.11% | 0.09% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -294.57M | -278.67M | -173.98M | -152.63M | -135.84M | -130.47M | -89.63M | -63.14M | -60.45M | -35.43M | -27.56M | -22.63M | -11.01M | -27.32K | -27.04K | -22.39K | -22.39K | -20K | -33.62K |
| Net Margin % | -411.19% | -412.95% | -322.89% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -61.95% | -60.17% | -13.99% | -12.36% | -4.12% | -45.57% | -41.95% | -4.46% | -70.59% | -28.57% | -21.81% | -105.44% | -40218.51% | -1.02% | -20.74% | 0% | -12% | 40.53% | - |
| Net Income (Continuing) | -294.57M | -278.67M | -173.98M | -152.63M | -135.84M | -130.47M | -89.63M | -63.14M | -60.45M | -35.43M | -27.56M | -22.63M | -11.01M | -27.32K | -27.04K | -22.39K | -22.39K | -20K | -33.62K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.32 | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -2.69 | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 | -0.01 |
| EPS Growth % | -59.52% | -57.43% | 2.88% | -2.46% | -3.05% | -16.57% | -11.92% | 12.21% | -13.16% | -3.4% | 35.53% | 15.24% | - | - | - | - | - | - | - |
| EPS (Basic) | - | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | -1.52 | -1.47 | -2.28 | -2.69 | -0.01 | -0.01 | -0.00 | -0.00 | -0.00 | -0.01 |
| Diluted Shares Outstanding | 88.61M | 87.68M | 86.16M | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.7M | 9.93M | 4.09M | 5M | 5M | 5M | 5M | 5M | 5M |
| Basic Shares Outstanding | 88.61M | 87.68M | 86.16M | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.7M | 9.93M | 4.09M | 5M | 5M | 5M | 5M | 5M | 5M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Clinical trial binary outcome
According to recent financial disclosures, Kura's revenue remains entirely non-operational, characterized by sporadic milestone payments that reached $18.3M in 2026Q1, highlighting the absence of a recurring commercial product base and the inherent volatility associated with relying on partnership-driven income streams for long-term financial sustainability.
The revenue profile is strictly transactional, reflecting the amortization of collaboration agreements rather than organic product demand. Investors should interpret these figures as indicators of partnership progress rather than a reliable indicator of future commercial scale or market penetration.
As reported in quarterly filings, R&D expenditures have steadily climbed from $32.5M in 2023Q4 to $65.3M in 2026Q1, demonstrating a clear commitment to advancing the ziftomenib pipeline despite the lack of corresponding growth in recurring revenue to offset these significant capital requirements.
The consistent upward trend in R&D spending suggests an aggressive clinical development strategy that prioritizes trial velocity over near-term expense discipline. This cost structure necessitates continuous external financing, as the current operating model is fundamentally designed to consume capital to reach pivotal regulatory milestones.
Based on the provided income statement data, Kura's operating margin has remained consistently negative, with the 2026Q1 operating loss of $78.8M underscoring the structural inability of current licensing-based revenue to cover the firm's substantial fixed overhead and clinical trial-related operating expenses.
The lack of operating leverage is expected for a clinical-stage entity, yet the widening gap between R&D investment and revenue generation warrants caution. Without a transition to a commercialized product, the company will likely continue to exhibit high sensitivity to capital market conditions.
Analysis of recent quarterly reports indicates that stock-based compensation, which reached $11.4M in 2025Q4, serves as a significant non-cash expense that obscures the true magnitude of the company's cash-based operational burn, complicating the assessment of underlying financial performance for potential investors.
The reliance on equity-based incentives is a standard practice in the biotech sector to preserve cash, but it effectively dilutes existing shareholders while masking the true cost of talent acquisition. Analysts should adjust for these non-cash items to better understand the actual cash runway remaining.
As evidenced by the $149M cash position relative to quarterly operating losses exceeding $70M, the company faces a precarious financial outlook that may necessitate dilutive equity raises, creating a significant risk for investors if clinical trial results fail to meet primary endpoints in the near term.
The market's valuation of Kura appears heavily contingent on the success of ziftomenib, leaving little room for error in clinical execution. Any delay in trial enrollment or regulatory feedback could exacerbate the existing cash burn, forcing management to seek capital under potentially unfavorable market conditions.
Quick answers to the most common questions about buying KURA stock.
For fiscal year 2025, Kura Oncology, Inc. (KURA) reported total revenue of $67.5M.
Kura Oncology, Inc. (KURA) reported a net loss of $278.7M for the fiscal year ending 2025.
Kura Oncology, Inc. (KURA) reported an operating income of $-303.6M, resulting in an operating profit margin of -449.9%. This margin reflects the operational efficiency of the business before interest and taxes.
Kura Oncology, Inc. (KURA) generated $67.4M in gross profit for the year, representing a gross profit margin of 99.9%. This demonstrates the company's core pricing power and production efficiency.